K. Miatkowski

发表

Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.

Daniel A Erlanson, D. M. Penny, Lihong Sun, 2011, Bioorganic & medicinal chemistry letters.

Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.

M. Zafari, P. Lawton, J. Browning, 1995, Journal of immunology.

A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties.

E. Padlan, N. Letvin, K. Reimann, 1997, AIDS research and human retroviruses.

Growth Factor Induction of Cripto-1 Shedding by Glycosylphosphatidylinositol-Phospholipase D and Enhancement of Endothelial Cell Migration*

C. Bianco, L. Strizzi, M. Mancino, 2007, Journal of Biological Chemistry.

An Intermediate pH Unfolding Transition Abrogates the Ability of IgE to Interact with Its High Affinity Receptor FcϵRIα*

S. Demarest, M. Kehry, J. Hopp, 2006, Journal of Biological Chemistry.

Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes.

C. Ambrose, C. Benjamin, P. Lawton, 1997, Journal of immunology.

Fucosylation of Cripto is required for its ability to facilitate nodal signaling.

B. Damon, H. Adkins, K. Williams, 2001, The Journal of biological chemistry.

Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines

M. Zafari, F. Mackay, C. Benjamin, 1996, The Journal of experimental medicine.

Identification of a Palmitic Acid-modified Form of Human Sonic hedgehog*

C. Ambrose, D. Baker, S. Bixler, 1998, The Journal of Biological Chemistry.

The ELAM ligand fucosyltransferase, ELFT, directs E-selectin binding to a secreted scaffold protein: a method to produce and purify large quantities of specific carbohydrate structures.

S. Goelz, K. Miatkowski, R. Lobb, 1993, The Biochemical journal.

Preparation and Characterization of Soluble Recombinant Heterotrimeric Complexes of Human Lymphotoxins and (*)

C. Ambrose, J. Browning, D. Griffiths, 1996, The Journal of Biological Chemistry.

Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes.

C. Ambrose, M. Zafari, F. Mackay, 1997, Journal of immunology.

Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.

Mohammad Zafari, Kevin P Williams, Ling Ling Chen, 2003, The Journal of clinical investigation.

Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.

B. Domon, D. Baker, R. Arduini, 2004, Protein expression and purification.

Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers.

M. Rogge, P. Hochman, A. Gill, 1995, Therapeutic immunology.

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

A. Lukashin, L. Griffith, S. Violette, 2006, Cancer research.

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases

L. Silvian, D. Baker, V. Hong, 2010, Protein science : a publication of the Protein Society.

Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines

M. Zafari, F. Mackay, C. Benjamin, 1996, The Journal of experimental medicine.

Signaling through the Lymphotoxin 13 Receptor Induces the Death of Some Adenocarcinoma Tumor Lines By Jeffrey L. Browning, Konrad Miatkowski, Irene Sizing,

M. Zafari, F. Mackay, C. Benjamin, 1996 .